Guardant Health Leads the Way in Blood-Based Single Cancer Screening
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.
GlobalData on MSN21h
FibroGen sells China unit to AstraZeneca for $160m
AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...